RxDoctor Payments Data

Ali Harake, MD

Internal Medicine · Fort Lauderdale, FLNPI 1154341535

Payments from drug & device makers

$915in general payments, 2019–2025

Across 45 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$282
  • Viiv Healthcare Company$279
  • Amgen$270
  • Theratechnologies Inc.$32
  • Braintree Laboratories, Inc.$19
  • Antares Pharma, Inc.$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$915100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$915 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$67,976
Medicare patients
250
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin46$679,197
BiktarvyBictegrav/Emtricit/Tenofov Ala154$651,954
TriumeqAbacavir/Dolutegravir/Lamivudi126$508,612
DescovyEmtricitabine/Tenofov Alafenam153$430,063
TivicayDolutegravir Sodium149$428,851
DovatoDolutegravir Sodium/Lamivudine101$428,103
GenvoyaElviteg/Cob/Emtri/Tenof Alafen87$348,870
PrezcobixDarunavir/Cobicistat85$260,557
OdefseyEmtricitab/Rilpiviri/Tenof Ala46$208,996
OzempicSemaglutide143$183,595
IsentressRaltegravir Potassium67$142,193
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf21$140,762
MounjaroTirzepatide90$104,535
Darunavir103$95,184
EliquisApixaban73$86,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$282$1,430,886394 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato$279$1,365,565376 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →